Related Experiment Videos
Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists
G A Sulyok1, C Gibson, S L Goodman
1Institut für Organische Chemie und Biochemie, Technische Universität München, Lichtenbergstrasse 4, D-85747 Garching, Germany.
Journal of Medicinal Chemistry
|June 1, 2001
Summary
Researchers developed novel nonpeptide integrin antagonists targeting alphavbeta3 integrins. These orally bioavailable compounds show high activity and selectivity, offering a promising new therapeutic approach.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Biochemistry
Background:
- Integrins, such as alphavbeta3 and alphaIIbbeta3, are key cell surface receptors involved in various physiological and pathological processes.
- Ligands like vitronectin and fibrinogen interact with integrins, mediating cellular adhesion and signaling.
- Developing small molecule antagonists for these integrins is a significant goal in drug discovery.
Purpose of the Study:
- To synthesize and screen a library of low molecular weight RGD (Arginine-Glycine-Aspartic acid) mimetics.
- To identify potent and selective nonpeptide antagonists for alphavbeta3 integrins with potential for oral bioavailability.
- To explore structural modifications for improved pharmacokinetic properties and metabolic stability.
Main Methods:
- Solid-phase synthesis of a diverse RGD mimetic library.
- High-throughput screening assay to determine inhibitory activity against ligand-integrin interactions (vitronectin/fibrinogen with alphavbeta3/alphaIIbbeta3).
- Structure-activity relationship (SAR) studies based on lead compound 1, including aromatic residue substitution and guanidine mimetic incorporation.
Main Results:
- Identification of highly active and selective nonpeptide alphavbeta3 integrin antagonists.
- Development of orally bioavailable compounds derived from an aza-glycine containing lead structure.
- Successful incorporation of aromatic residues and guanidine mimetics to enhance activity and pharmacokinetic profiles.
- Introduction of azacarba analogues, a novel peptidomimetic approach, demonstrating increased metabolic stability.
Conclusions:
- The study successfully developed potent and selective nonpeptide alphavbeta3 integrin antagonists with favorable oral bioavailability.
- Structural modifications, including aromatic substitutions and guanidine mimetics, are effective in optimizing antagonist properties.
- Azacarba analogues represent a novel and promising peptidomimetic strategy for enhancing metabolic stability in RGD mimetics.